CPT code 19085 represents an MRI-guided percutaneous breast biopsy of a single lesion, with the option to place a localization device during the same procedure. This image-guided diagnostic intervention is an important tool in breast cancer diagnosis, enabling targeted tissue sampling when lesions are best visualized with magnetic resonance imaging. Nationally, MRI-guided breast biopsy addresses cases where mammography or ultrasound are insufficient, supporting earlier and more accurate diagnosis for patients with MRI-only lesions.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The analysis covers coding context, typical sites of service, and common billing modifiers. Readers will find concise benchmarks on payer coverage patterns, clinical indications that commonly drive use of this code, and notes on documentation elements linked to appropriate coding. The publication also outlines operational considerations for facilities performing MRI-guided breast biopsies, including site-of-service implications and the dual role of biopsy with concurrent localization.

This summary is intended for a national audience of practice managers, billing professionals, and clinical leaders who need a clear, concise reference to CPT code 19085, its clinical application, and payer landscape. Data not available in the input is noted where relevant.